In high-income country health systems such as the US, UK, and Norway, unselected BRCA1/BRCA2/PALB2 multigene testing at BC diagnosis has been reported to be cost-effective compared with FH/clinical-criteria-based testing [9,17,18] and has led to some calls for policy change [19]. This evidence concerns the gene BRCA1 and breast cancer.